RESEARCH DATABASE

InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Impact of dapagliflozin therapy on renal protection and kidney morphology in patients with uncontrolled type 2 diabetes mellitu

Endocrinology
Nephrology
Author
Sugiyama et al
Used Parameters : BW, BMI, TBW, BFM, PBF
Publication Year : 2018
Country : Japan
Journal : Journal of Clinical Medicine Research
Background We examined whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) dapagliflozin can improve urine albumin-to-creatinine ratio (UACR) associated with a reduction in body weight or body fat in patients with type 2 diabetes mellitus (T2DM). Methods We prospectively recruited T2DM patients having inadequate glycemic control (hemoglobin A1c (HbA1c)> 7.0%) not on SGLT2i therapy. We treated the patients with add-on dapagliflozin treatment or intensification of non-SGLT2 inhibitor therapies for 6 months …
Full text
List
Powered by KBoard